Core Viewpoint - A securities class action lawsuit has been filed against Krispy Kreme, alleging false or misleading statements regarding its partnership with McDonald's and the subsequent decline in product demand [1][7]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals or entities who purchased Krispy Kreme securities between February 25, 2025, and May 7, 2025 [1]. - Investors have until July 15, 2025, to request to be appointed as Lead Plaintiff for the class [2]. Group 2: Allegations Against Krispy Kreme - Krispy Kreme allegedly failed to disclose a significant decline in demand for its products at McDonald's following the initial marketing launch [7]. - This decline resulted in lower average sales per location and indicated that the partnership with McDonald's was not profitable [7]. - The issues raised in the lawsuit suggest risks to the continuation of the partnership, leading Krispy Kreme to pause its expansion to new McDonald's locations [7]. Group 3: Legal Representation - Wolf Haldenstein Adler Freeman & Herz LLP, a law firm with over 125 years of experience in securities litigation, is representing the investors [4]. - The firm emphasizes its commitment to seeking justice for investors who have suffered financial harm due to misrepresented statements [4].

Core Points - Savara Inc. received a refusal to file letter from the FDA regarding its Biologics License Application for MOLBREEVI, intended for treating autoimmune pulmonary alveolar proteinosis [1] - Following the FDA's decision, Savara's stock price experienced a decline [1] Company Information - Holzer & Holzer, LLC is investigating whether Savara complied with federal securities laws in light of the recent FDA decision [1] - The law firm specializes in representing shareholders and investors in litigation, including class action and derivative litigation, and has recovered hundreds of millions of dollars for affected shareholders since its founding in 2000 [3]

NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) between October 31, 2024, to April 30, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Joseph Hauser v. Organon & Co., et al. (Case No. 2:25-cv-05322) has been commenced in the United States District Court for the District of New Jersey ...

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) between August 8, 2024, to May 8, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Karthik Trichur Sundaram v. Iovance Biotherapeutics, Inc., et al. (Case No. 3:25-cv-04177) has been commenced in the United States Dist ...

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP, a distinguished law firm with over 125 years of history, informs investors that a class action lawsuit has been filed Open Lending Corporation (Open Lending or the Company) (NASDAQ: LPRO) on behalf of a class consisting of all investors that purchased or otherwise acquired Open Lending securities between February 24, 2022 and March 31, 2025, both dates inclusive (the "Class Period"). Deadline to sign up: If you are an inve ...

Core Viewpoint - A class action lawsuit has been filed against Compass Group Diversified Holdings LLC due to alleged failures in financial reporting and internal controls, leading to significant stock price decline following the revelation of these issues [1][3][4]. Company Summary - The lawsuit, Nicholas Moreno v. Compass Group Diversified Holdings LLC, was initiated for investors who acquired securities between May 1, 2024, and May 7, 2025 [1]. - Allegations include the company's lack of effective internal controls over financial reporting and failure to disclose critical information regarding its subsidiary, Lugano Holding, Inc., which had undisclosed financing arrangements and irregularities in financial metrics [3]. - On May 7, 2025, Compass announced that its fiscal 2024 financial statements could no longer be relied upon due to an internal investigation into Lugano, leading to the resignation of Lugano's CEO without severance [4]. Market Impact - Following the announcement of the investigation, Compass' stock price plummeted from $17.25 per share on May 7, 2025, to $6.55 per share on May 8, 2025, indicating a dramatic loss in market value [5].

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP, a distinguished law firm with over 125 years of history, informs investors that a class action lawsuit has been filed against Civitas Resources, Inc. ("Civitas " or the "Company") (NYSE: CIVI) on behalf of a class consisting of all investors that purchased or otherwise acquired Civitas securities between February 27, 2024 and February 24, 2025, both dates inclusive (the "Class Period"). Deadline to sign up: If you are an i ...

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Humana Inc. (“Humana” or the “Company”) (NYSE:HUM). The investigation concerns whether Humana and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On May 1, 2025, the U.S. Department of Justice filed a complaint against insurance broker organizations, including Humana, alleging t ...

Core Viewpoint - A class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. for misleading investors regarding the approval prospects of its Biologics License Application for lomab-B, leading to significant stock price decline [1][4]. Group 1: Lawsuit Details - The class action lawsuit is filed in the U.S. District Court for the Southern District of New York on behalf of investors who acquired Actinium securities from October 31, 2022, to August 2, 2024 [1]. - Investors have until May 27, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Regulatory Update - On August 5, 2024, Actinium announced that the FDA determined the data from its Sierra trial did not support a BLA filing for lomab-B, necessitating an additional clinical study [3]. - Following this announcement, Actinium's share price fell by $3.69, or approximately 59%, from $6.17 on August 2, 2024, to $2.48 on August 5, 2025 [3]. Group 3: Allegations - The complaint alleges that during the Class Period, Actinium misled the market into believing that the data submitted for its BLA would meet FDA guidelines for acceptance and approval [4].

NEW YORK , May 05, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). The investigation concerns whether Arvinas and/or certain of its officers have violated the federal securities laws. [LEARN MORE ABOUT THE INVESTIGATION] On May 1, 2025, Arvinas and its partner Pfizer announced that they would discontinue development of vepdegestrant, an oral SERD for HR-positive breast cancer. The move eliminated ...